explore -WSS

explore

author：Wikipedia 2025-09-30 00:03:52 - browse：81

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： General Catalyst, Summa Health deal will turn on physician buy

WSS

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Three trends to watch in biotech in 2024

Virtual care provider acquires bankrupt Pear's prescription apps

Quicker fix for pulse oximeters urged during FDA public meeting

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Drinking less cuts risk of oral cavity, esophageal cancer: Report

focus

explore

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

As demand for Covid shots wanes, Moderna seeks its next success

Time to name cancers by genetics, not organ of origin, expert says

Drug repurposing or repositioning? The language matters

David Ricks of Eli Lilly: best biopharma CEO of 2023

The cancer drug shortage isn’t new — and neither are the solutions

SAMSHA loosens regulations on methadone treatment centers

Anesthesiologist group: stop taking Ozempic before surgery

Christmas in the PICU brings some surprising joy

explore

Some dementia cases could be undiagnosed liver disease

Time to name cancers by genetics, not organ of origin, expert says

Christmas in the PICU brings some surprising joy

Apple Vision Pro: A first look at health apps on the new VR headset

Woodcock on FDA’s accelerated approval and her next chapter

Vertex non

hotspot

hotspot

explore

knowledge